Recent advances in the therapy of amyotrophic lateral sclerosis: Focus on excitotoxicity

Functional Neurology

Volumn 16, Issue 4 SUPPL., 2001, Pages 189-202

  Brighina, Laura ^a   Sala, Gessica ^a   Ceresa, Chiara ^a   Tremolizzo, Lucio ^a   Ferrarese, Carlo ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

ALS; Clinical trial; Excitotoxicity; Oxidative stress; Riluzole; Therapy

Indexed keywords

ACETYLCYSTEINE; AMITRIPTYLINE; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BRANCHED CHAIN AMINO ACID; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DEXTROMETHORPHAN; DIAZEPAM; FLUOXETINE; GABAPENTIN; GLUTAMATE DEHYDROGENASE; GLUTAMATE RECEPTOR ANTAGONIST; LORAZEPAM; MAGNESIUM; MEMANTINE; OPIATE; PHENYTOIN; QUININE SULFATE; RECOMBINANT BRAIN DERIVED NEUROTROPHIC FACTOR; RECOMBINANT CILIARY NEUROTROPHIC FACTOR; RECOMBINANT SOMATOMEDIN C; RILUZOLE; SELEGILINE; SERTRALINE; TETRAZEPAM; TIZANIDINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; XALIPRODEN; NERVE GROWTH FACTOR; NEUROTOXIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANOREXIA; ASTHENIA; BRAIN STEM INJURY; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; CONVULSION; DAILY LIFE ACTIVITY; DEATH; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSARTHRIA; DYSPHAGIA; DYSPNEA; ENZYME ACTIVITY; ENZYME METABOLISM; FACIAL NERVE PARALYSIS; FASCICULATION; FEVER; HUMAN; HYPERSALIVATION; MOTOR NEURON DISEASE; MUSCLE CRAMP; NERVE CELL STIMULATION; NERVE DEGENERATION; NONHUMAN; ONSET AGE; OXIDATIVE STRESS; PATHOGENESIS; PHYSIOTHERAPY; PROGNOSIS; QUALITY OF LIFE; RESPIRATORY FAILURE; RISK ASSESSMENT; SIDE EFFECT; SPASTICITY; STANDARDIZATION; SURVIVAL; TOXICITY TESTING; TRACHEOSTOMY; WEIGHT REDUCTION; DRUG ANTAGONISM; METABOLISM; METHODOLOGY; NEUROLOGY; PATHOPHYSIOLOGY; REVIEW;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIALS; HUMANS; NERVE GROWTH FACTORS; NEUROLOGY; NEUROTOXINS; RESEARCH DESIGN;

EID: 0035544943     PISSN: 03935264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (61)

1. Partial deficiency of manganese superoxide dismutase exacerbates a transmouse model of amyotrophic lateral sclerosis
2. Molecular genetic analysis of the APEX nuclease gene in amyotrophic lateral sclerosis
3. Benefit of vitamin E, riluzole and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis
4. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis
5. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole
6. Evidence for the validity and reliability of the ALS assessment questionnaire: The ALS-AQ40
7. Brain glutamate deficiency in amyotrophic lateral sclerosis
8. The neuroexcitotoxic amino acids glutamate and aspartate are altered in the spinal cord and brain in amyotrophic lateral sclerosis
9. Abnormal glutamate metabolism in amyotrophic lateral sclerosis
10. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis
11. Amyotrophic lateral sclerosis: Amino acid levels in plasma and cerebrospinal fluid
12. Assessment of reliability and biological significance of glutamate levels in cerebrospinal fluid
13. Decreased brain and spinal cord glutamate transport in amyotrophic lateral sclerosis
14. Selective loss of glutamate transporter GLT-1 in amyotrophic lateral sclerosis
15. Aberant RNA processing in a neurodegenerative disease: The cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis
16. Anternative splicing of the glutamate transporter EAAT2
17. Splicing of the glutamate transporter EAAT2: A candidate gene of amyotrophic lateral sclerosis
18. Identification of alternative splicing forms of GLT-1 mRNA in the spinal cord of amyotrophic lateral sclerosis patients
19. Glutamate transporter EAAT2 splice variants occur not only in ALS, but also in AD and controls
20. Intron 7 retention and exon 9 skipping EAAT2 mRNA variants are not associated with amyotrophic lateral sclerosis
21. Mutations in Cu, Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis
22. Oxidative damage to protein in sporadic motor neuron disease spinal cord
23. 3H-glutamate uptake with different potencies in rodent central nervous system regions expressing different transporter subtypes
24. Glutamate uptake inhibition by oxygen free radicals in rat cortical astrocytes
25. Glutamate uptake is inhibited by arachidonic acid and oxygen radicals via two distinct and additive mechanisms
26. Protein modification by the lipid perodixation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients
27. SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter
28. The human platelet as a model for the glutamatergic neuron: Platelet uptake of L-glutamate
29. Molecular characterization of glutamate transporters in human platelets
30. Decreased platelet glutamate uptake in patients with amyotrophic lateral sclerosis
31. Evaluation of antioxidants, protein and lipid oxidation products in blood from sporadic amyotrophic lateral sclerosis patients
32. Blood oxidative stress in amyotrophic lateral sclerosis
33. A controlled trial of riluzole in amyotrophic lateral sclerosis
34. A dose-ranging study of riluzole in amyotrophic lateral sclerosis
35. Amyotrophic lateral sclerosis, excitotoxicity, and riluzole
36. Pilot trial of branched-chain aminoacids in amyotrophic lateral sclerosis
37. Emerging perspectives on the mechanism of action of gabapentin
38. A placebo-controlled trial of gabapentin in amyotrophic lateral sclerosis
39. High dose dextromethorphan in amyotrophic lateral sclerosis: Phase 1 safety and pharmacokinetic studies
40. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis
41. Double blind cross over trial with deprenyl in amyotrophic lateral sclerosis
42. A phase I/II study of recombinant brain-derived neurotrophic in patients with ALS
43. A controlled trial of recombinant methionyl human BDNF (r-met Hu BDNF) in amyotrophic lateral sclerosis
44. Disruption of the CNTF gene results in motor neuron degeneration
45. Marked depletion of ciliary neurotrophic factor in ventral horn of spinal cord but not cerebral motor cortex in mayotrophic lateral sclerosis
46. Insulin-like growth factor I increases brain growth and central nervous system myelination in transgenic mice
47. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group
48. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group
49. Neuroprotective effects of SR57746A in central and peripheral models in rodents and primates
50. Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis
51. A retrospective study of percutaneous endoscopic gastrostomy in ALS patients during the BDNF and CNTF trials
52. Noninvasive ventilation allows gastrostomy tube placement in patients with advanced ALS
53. Assessment of depression in patients with motor neuron disease and other neurologically disabling illness
54. Gene therapy of murine motor neuron disease using adenoviral vectors for neutrophic factors
55. Treatment of amyotrophic lateral sclerosis using gene therapy approach
56. Apoptosis in the nervous system: Morphological features, methods, pathology and prevention
57. Neuronal death in amyotrophic lateral sclerosis is apoptosis: Possible contribution of a programmed cell death mechanism
58. Grafting immortalized neurons to the CNS
59. Transplantation of neural progenitor and stem-like cells as a strategy for gene therapy and repair of neurodegenerative diseases
60. Stem cells step closer to the clinic. Paralysis partially reversed in rats with ALS-like disease